A Phase 3 interventional study of Sapablursen and Placebo in Polycythemia Vera, sponsored by Ono Pharmaceutical Co., Ltd.. Recruiting at 38 sites in 9 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-29.
Sponsored by Ono Pharmaceutical Co., Ltd. · Phase 3, Interventional, and Treatment
Poland, United Kingdom, Brazil, Hungary, Austria, France
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 179 studies in Polycythemia Vera with a site in United States — 22 open to participants now, 34 under way, 7 of them phase 3. Polycythemia Vera · United States.
Among the 179 studies in Polycythemia Vera with a site in United States, this one is the 9th largest by planned enrollment of the 150 interventional ones that give a count, is one of 6 that started in 2026, is one of 18 in phase 3, reaches primary completion later than 23 of the 33 other live ones, and was the 175th registered.
278 studies on the registry are indexed under Polycythemia Vera; 53 are open to participants now.
Browse Polycythemia Vera studies →22 of the 179 studies in Polycythemia Vera with a site in United States are open now. Recruiting first, the newest first:
Memorial Sloan Kettering Cancer Center · Sites in United States
Ages 18+
Merck Sharp & Dohme LLC · Sites in United States, Canada, Israel
Ages 18+
Massachusetts General Hospital · Sites in United States
Healthy volunteers
Incyte Corporation · Sites in United States, Australia, Belgium and 8 more countries
Ages 18+
Prelude Therapeutics Incorporated · Sites in United States, Australia, France and 2 more countries
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 42 Polycythemia Vera studies recruiting now, 38 (90%) set no upper age limit and 1 (2%) stops at 75 or younger; 4 take children under 18; 1 takes healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
179 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 61 · Phase 2 89 · Phase 3 20
First in 1992; this study’s year is marked. 6 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 250 is above the median of 52 across 204 interventional studies indexed under Polycythemia Vera.
Median enrollment 40 across the 150 interventional studies, 678 across the 15 observational. Of the 135 that completed or were terminated, 54 (40%) have results posted.
This tab as a report to print or save as PDF → With an account.
43 of 179 have an industry lead sponsor. The 10 most frequent:
This study is registered under Ono Pharmaceutical Co., Ltd., one of the names counted as Ono Pharmaceutical Co. Ltd. Under that name alone:
Ono Pharmaceutical Co., Ltd. is the lead sponsor of 49 studies on the registry; 18 are open to participants now.
Ono Pharmaceutical Co. Ltd has 1 study filed under Polycythemia Vera — fewer than ten, so there is no comparison to draw.
9 of the studies in Polycythemia Vera with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04041050AbbVieA Study Evaluating Safety and Tolerability, and Pharmacokinetics of Navitoclax Monotherapy and in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasm | 2026-12-31 |
| NCT07203768FROM- Fondazione per la Ricerca Ospedale di Bergamo- ETSA ELN-Multicenter Study on Phenotypic Evolution and Clinical Outcomes | 2026-12-31 |
| NCT06063486University of Southern CaliforniaCurcumin to Improve Inflammation and Symptoms in Patients With Clonal Cytopenia of Undetermined Significance, Low Risk Myelodysplastic Syndrome, and Myeloproliferative Neoplasms | 2026-12-31 |
| NCT05714072Memorial Sloan Kettering Cancer CenterA Study of Ruxolitinib in Combination With Abemaciclib for the Treatment of Myelofibrosis | 2027-01 |
| NCT03862157M.D. Anderson Cancer CenterAzacitidine, Venetoclax, and Pevonedistat in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia | 2027-01-31 |
Add all 9 to your calendar (.ics) → With an account.
Among the 179 studies in Polycythemia Vera with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the efficacy and safety of sapablursen when added on to current standard of care (SOC) for Polycythemia Vera (PV) therapy. The study will be conducted in three sequential parts (Part 1a blinded treatment, Part 1b open-label treatment, \& Part 2 long-term extension). Participants may receive treatment for up to 156 weeks.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Sapablursen (32 Weeks) - Sapablursen (124 Weeks Open-label)
Drug: Sapablursen
Placebo (32 Weeks) - Sapablursen (124 Weeks Open-label)
Drug: Sapablursen · Drug: Placebo
Administered subcutaneously (SC)
Also known as: ONO-0530, ISIS 702843
Administered SC
Percentage of Participants with Absence of Phlebotomy Eligibility
Response is defined as absence of phlebotomy eligibility.
Time frame: Week 20 through Week 32
Number of Phlebotomies
Time frame: Week 0 through Week 32
Percentage of Participants with Hct Control
Defined as all local laboratory Hct \<45% without phlebotomy.
Time frame: Week 0 to Week 32
Change from Baseline in Patient Reported Outcomes Measurement Information System (PROMIS) Fatigue Short Form Total T-score
Time frame: Baseline, Week 32
Change from Baseline in Myelofibrosis Symptom Assessment Form (MFSAF) Total Symptom Score (TSS)
Time frame: Baseline, Week 32
Percentage of Participants with Absence of Phlebotomy Eligibility
Response is defined as absence of phlebotomy eligibility.
Time frame: Week 20 through Week 52
Number of Phlebotomies
Time frame: Week 0 through Week 52
Percentage of Participants with Hct Control
Defined as all local laboratory Hct \<45% without phlebotomy.
Time frame: Week 0 through Week 52
Plan to share: No
No publications or documents are linked to this record.
Started May 2026 (actual). Primary completion is estimated for Sep 2028, 28 months after the start.
How these figures are worked out, and which studies are left out of them.
Poland, United Kingdom, Brazil, Hungary, Austria, France
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Sapablursen
Ono Pharmaceutical Co., Ltd. →